Barcelona Institute for Global Health

Insud Pharma secures $2.7M from Gates Foundation for Phase II trial of thermostable sublingual oxytocin to prevent postpartum hemorrhage, aiming to reduce maternal mortality in low-resource regions.

Insud Pharma receives $2.7 million from the Bill & Melinda Gates Foundation for a Phase II trial to determine the optimal dose of sublingual oxytocin to prevent postpartum hemorrhage, aiming to save lives of over 70,000 pregnant women annually. The thermostable oxytocin tablets do not require refrigeration, making them accessible in low-resource settings. The trial, expected to start in Q1 2025, will involve 180 participants.

A study finds that over a third of Americans remain mistrustful of COVID vaccine science, with levels unchanged since 2021. Personal loss due to COVID significantly increases trust in vaccine experts. Future public health messaging should consider diverse backgrounds to build trust.

A study found 56% of 2022's European heat-related deaths were due to anthropogenic climate change, equating to over 38,000 excess fatalities.